NKT Therapeutics Announces Hiring of Barbara Finck, M.D. as Chief Medical Officer

WALTHAM, Mass.--(BUSINESS WIRE)-- NKT Therapeutics, Inc., a privately held biotechnology company, today announced the appointment of Barbara Finck, M.D. to the position of Chief Medical Officer.

“We are delighted to add someone with Barbara’s background and depth of experience,” said Robert Mashal, Chief Executive Officer of NKT Therapeutics. “This important addition to the NKT Therapeutics senior management team further advances our goal of building a pipeline of first-in-class NKT cell-directed therapeutics to treat autoimmune and inflammatory diseases, cancer, infectious diseases, and dermatitis.”

Dr. Finck most recently was the Senior VP Research and Development and Chief Medical Officer at Osprey Pharmaceuticals. Prior to that, she served as the VP Clinical Development at Eos Biotechnology and then at Protein Design Labs following their acquisition of Eos. Previously, Dr. Finck was at Immunex Corporation, where she was the lead clinician in the development of etanercept (Enbrel®). She began her industry career at Alza. Dr. Finck obtained her MD degree and completed her residency in internal medicine and fellowship in rheumatology at the University of California, San Francisco. She is the co-author of numerous scientific publications appearing in Science, the New England Journal of Medicine, and Lancet. Previously, she served as a member of the Scientific Advisory Board of the Association for Lupus Research.

About NKT Therapeutics, Inc.

NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company’s mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat autoimmune and inflammatory diseases, cancer, infectious diseases, and dermatitis. For more information on the company, please visit http://www.nktrx.com.



CONTACT:

NKT Therapeutics
Robert Mashal, 781-684-0290
[email protected]
or
Kureczka/Martin Associates
Joan Kureczka, 415-821-2413
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  AIDS  Biotechnology  Infectious Diseases  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.